Skip to main content

Drug Interactions between almotriptan and rufinamide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

almotriptan rufinamide

Applies to: almotriptan and rufinamide

MONITOR: Rufinamide may modestly or moderately decrease the plasma concentrations and therapeutic effects of drugs that are CYP450 3A4 substrates. The mechanism is enhanced metabolism by CYP450 3A4 enzyme induction. Enzyme induction is more pronounced with larger doses of rufinamide. After treatment with rufinamide 400 mg twice daily for 11 days, the clearance of triazolam was increased by 55% and the exposure was decreased by 36%.

MANAGEMENT: During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose. Dose adjustments of the coadministered drug may be required if an interaction is suspected. The manufacturer also recommends that monitoring should be considered during concomitant use of drugs with a narrow therapeutic index, including digoxin and warfarin.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2008) "Product Information. Banzel (rufinamide)." Eisai Inc

Drug and food interactions

Moderate

rufinamide food

Applies to: rufinamide

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of rufinamide. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of rufinamide. In healthy volunteers, administration of a single 400 mg dose of rufinamide with food resulted in an approximately 56% increase in mean peak plasma concentration (Cmax) and a 34% increase in systemic exposure (AUC) compared to administration during a fasting state.

MANAGEMENT: To ensure maximal oral absorption, it is preferable to administer rufinamide with food. Patients receiving rufinamide should be advised to avoid consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how rufinamide affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (1)
  1. (2008) "Product Information. Banzel (rufinamide)." Eisai Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer